Show simple item record

dc.contributor.authorVitale, I
dc.contributor.authorYamazaki, T
dc.contributor.authorWennerberg, E
dc.contributor.authorSveinbjørnsson, B
dc.contributor.authorRekdal, Ø
dc.contributor.authorDemaria, S
dc.contributor.authorGalluzzi, L
dc.date.accessioned2021-04-12T09:28:06Z
dc.date.available2021-04-12T09:28:06Z
dc.date.issued2021-01-11
dc.identifier.citationTrends in cancer, 2021
dc.identifier.issn2405-8033
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4516
dc.identifier.eissn2405-8025
dc.identifier.doi10.1016/j.trecan.2020.12.012
dc.description.abstractAccumulating preclinical and clinical evidence indicates that high degrees of heterogeneity among malignant cells constitute a considerable obstacle to the success of cancer therapy. This calls for the development of approaches that operate - or enable established treatments to operate - despite such intratumoral heterogeneity (ITH). In this context, oncolytic peptides stand out as promising therapeutic tools based on their ability to drive immunogenic cell death associated with robust anticancer immune responses independently of ITH. We review the main molecular and immunological pathways engaged by oncolytic peptides, and discuss potential approaches to combine these agents with modern immunotherapeutics in support of superior tumor-targeting immunity and efficacy in patients with cancer.
dc.formatPrint-Electronic
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
dc.titleTargeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides.
dc.typeJournal Article
dcterms.dateAccepted2020-12-15
rioxxterms.versionAM
rioxxterms.versionofrecord10.1016/j.trecan.2020.12.012
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
rioxxterms.licenseref.startdate2021-01-11
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfTrends in cancer
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radiation-enhanced Immunotherapy
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radiation-enhanced Immunotherapy
pubs.publication-statusPublished
pubs.embargo.termsNot known
icr.researchteamRadiation-enhanced Immunotherapy
icr.researchteamRadiation-enhanced Immunotherapyen_US
dc.contributor.icrauthorWennerberg, Eriken


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record